Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

74.87USD
23 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$74.87
Open
--
Day's High
--
Day's Low
--
Volume
600
Avg. Vol
369,014
52-wk High
$80.03
52-wk Low
$31.39

Latest Key Developments (Source: Significant Developments)

Alnylam Pharmaceuticals reports proposed public offering of common stock
Tuesday, 23 May 2017 04:04pm EDT 

May 23 (Reuters) - Alnylam Pharmaceuticals Inc ::Alnylam Pharmaceuticals announces proposed public offering of common stock.Says offering 5.00 million common shares.  Full Article

Alnylam Pharmaceuticals appoints Manmeet Soni as chief financial officer
Tuesday, 9 May 2017 08:00am EDT 

May 9 (Reuters) - Alnylam Pharmaceuticals Inc ::Alnylam Pharmaceuticals Inc - appointment of Manmeet S. Soni as chief financial officer.  Full Article

Alnylam Pharmaceuticals files for potential mixed shelf offering
Friday, 5 May 2017 08:49am EDT 

May 5 (Reuters) - Alnylam Pharmaceuticals Inc : :Files for potential mixed shelf offering; size not disclosed .  Full Article

Alnylam Pharmaceuticals reports Q1 loss per share of $1.25 including items
Friday, 5 May 2017 08:00am EDT 

May 5 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam pharmaceuticals reports first quarter 2017 financial results and highlights recent period activity.Q1 revenue $19 million versus I/B/E/S view $23.6 million.Q1 loss per share $1.25 including items.  Full Article

ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN
Wednesday, 26 Apr 2017 08:00am EDT 

April 26 (Reuters) - Alnylam Pharmaceuticals Inc :ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS.REMAINS ON TRACK TO PRESENT TOP-LINE RESULTS FROM ITS ONGOING APOLLO PHASE 3 STUDY OF PATISIRAN IN MID-2017.ALNYLAM PHARMA - RESULTS DEMONSTRATE THAT PATISIRAN HAS POTENTIAL TO HALT OR IMPROVE NEUROPATHY PROGRESSION ACROSS A BROAD RANGE OF NEUROLOGIC IMPAIRMENT.ALNYLAM PHARMA - PHASE 2 OLE PATIENTS HAVE ROLLED OVER TO ONGOING, GLOBAL APOLLO-OLE TRIAL, PLAN TO PRESENT 36-MONTH DATA FROM COHORT OF PATIENTS IN LATE 2017.ALNYLAM PHARMA - PATISIRAN FOUND TO BE WELL TOLERATED, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS FOR UP TO 25 MONTHS OF TREATMENT OR DRUG-RELATED DISCONTINUATIONS.  Full Article

Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran
Wednesday, 26 Apr 2017 07:00am EDT 

April 26 (Reuters) - Medicines Co :The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran.Medicines co- nda submission anticipated at or around end of 2019.Medicines co- company has received final, end-of-phase ii meeting minutes from fda.  Full Article

Invitae Corp announces a program in partnership with Alnylam Pharmaceuticals
Monday, 3 Apr 2017 07:30am EDT 

Alnylam Pharmaceuticals Inc :Announced a program in partnership with Alnylam Pharmaceuticals to provide genetic testing for hereditary ATTR (HATTR) amyloidosis.  Full Article

Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity
Wednesday, 8 Feb 2017 04:00pm EST 

Alnylam Pharmaceuticals Inc : Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity . Q4 revenue $17.5 million versus $7.6 million . Q4 revenue view $11 million -- Thomson Reuters I/B/E/S . Alnylam Pharmaceuticals Inc says expects to end 2017 with greater than $700 million in cash .Alnylam Pharmaceuticals Inc says also in early 2017, Alnylam plans to initiate ATLAS phase 3 program for fitusiran.  Full Article

ALNYLAM PRESENTS NEW DATA ON FITUSIRAN AT EAHAD
Thursday, 2 Feb 2017 11:45am EST 

Alnylam Pharmaceuticals Inc : ALNYLAM PHARMACEUTICALS INC - ANNOUNCED NEW RESULTS FROM AN EXPLORATORY ANALYSIS OF ITS PHASE 1 STUDY WITH FITUSIRAN . ALNYLAM PHARMA - NEW PHASE 1 RESULTS SHOWS EFFECTIVE BLEED MANAGEMENT WITH REPLACEMENT FACTOR AND BYPASSING AGENTS DURING FITUSIRAN ADMINISTRATION . ALNYLAM PHARMA- ANALYSIS OF BLEED MANAGEMENT DURING FITUSIRAN ADMINISTRATION SHOWED BREAKTHROUGH BLEEDS WERE EFFECTIVELY MANAGED . ALNYLAM PHARMACEUTICALS INC SAYS CONTINUE TO ADVANCE TOWARD START OF ATLAS PHASE 3 CLINICAL PROGRAM IN EARLY 2017 .ALNYLAM PHARMACEUTICALS INC - STABILITY STUDY RESULTS SUPPORT A GREATER THAN TWO YEAR PRODUCT SHELF-LIFE AT ROOM TEMPERATURE STORAGE CONDITIONS.  Full Article

Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision
Monday, 14 Nov 2016 08:00am EST 

Alnylam Pharmaceuticals Inc : Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders . Sanofi genzyme elects not to opt in for ALN-AS1 in acute hepatic porphyrias . Alnylam intends to commercialize ALN-AS1 globally upon product approval . Co, Sanofi Genzyme will co-develop and co-commercialize fitusiran in U.S., Canada, Western Europe . Alnylam pharma - Sanofi Genzyme will be required to make payments up to $75 million upon achievesanment of development, regulatory milestones for fitusiran .On track to initiate fitusiran Phase 3 program in early 2017.  Full Article

More From Around the Web